H
Heart Metabolics
Cardiometabolic therapy for hypertrophic cardiomyopathy orphan disease
About Heart Metabolics
Heart Metabolics was a biopharmaceutical company focused on developing treatments for cardio-metabolic diseases, particularly hypertrophic cardiomyopathy (HCM). The company was founded in 2013 by Professor Michael Frenneaux and Dr. Houman Ashrafian, who discovered that the known drug perhexiline could potentially reverse adverse cardiac energetics and heart failure symptoms associated with HCM.
The company's primary focus was the clinical development of its lead drug candidate, perhexiline, a carnitine palmitoyl-transferase (CPT) inhibitor. Perhexiline works by shifting the heart's energy metabolism from fatty acid to glucose utilization, which is believed to improve myocardial energetics and normalize the energy imbalance caused by the genetic defects in HCM. The company's strategy was to repurpose this existing drug, which had received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in 2012 for treating moderate-to-severe heart failure in HCM patients.
In January 2013, the UK-based entity secured $4 million in a Series A round to advance U.S. clinical development. Following this, a new Irish biotechnology company, Heart Metabolics Limited, was launched in April 2014 with a $20 million Series A financing from investors including venBio, Seroba Life Sciences, Brandon Capital Partners, and AshHill. These funds were used to acquire the Phase 3-ready perhexiline candidate from the original UK company, HMBL Limited. The company reached an agreement with the FDA under a Special Protocol Assessment (SPA) for a single, pivotal Phase 3 trial. A Phase 2b study was initiated in August 2016 to further demonstrate the drug's safety and efficacy. According to Tracxn, the company is now considered deadpooled.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2014 | $20M | $80M | AshHill Biomedical · Seroba Life Sciences · venBio Partners | — |
| SERIES A✓Equity / VC | Jan 2013 | $4M | $16M | AshHill Biomedical | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Heart Metabolics is 0 monthly website visits. Heart Metabolics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Heart Metabolics in the Dublin ecosystem
The Heart Metabolics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
AshHill Biomedical
Seroba Life Sciences
venBio Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Heart Metabolics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Heart Metabolics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









